Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Exagen (XGN) over the last 8 years, with Q3 2025 value amounting to $2.7 million.

  • Exagen's Free Cash Flow rose 21489.45% to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$11.2 million, marking a year-over-year decrease of 9407.07%. This contributed to the annual value of -$14.0 million for FY2024, which is 846.3% up from last year.
  • Latest data reveals that Exagen reported Free Cash Flow of $2.7 million as of Q3 2025, which was up 21489.45% from -$3.0 million recorded in Q2 2025.
  • Over the past 5 years, Exagen's Free Cash Flow peaked at $8.2 million during Q4 2023, and registered a low of -$12.5 million during Q2 2022.
  • Its 5-year average for Free Cash Flow is -$5.2 million, with a median of -$5.9 million in 2021.
  • Per our database at Business Quant, Exagen's Free Cash Flow crashed by 15138.83% in 2021 and then surged by 23425.08% in 2023.
  • Quarter analysis of 5 years shows Exagen's Free Cash Flow stood at -$7.1 million in 2021, then rose by 13.65% to -$6.1 million in 2022, then skyrocketed by 234.25% to $8.2 million in 2023, then crashed by 99.82% to $15000.0 in 2024, then soared by 17693.33% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, -$3.0 million for Q2 2025, and -$10.8 million during Q1 2025.